MARKET

MRNS

MRNS

Marinus Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.460
+0.245
+7.62%
Pre Market: 3.460 0 0.00% 05:25 09/21 EDT
OPEN
3.340
PREV CLOSE
3.215
HIGH
3.690
LOW
3.110
VOLUME
7.75M
TURNOVER
--
52 WEEK HIGH
4.070
52 WEEK LOW
1.010
MARKET CAP
422.79M
P/E (TTM)
-3.4865
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
The Daily Biotech Pulse: Moderna Inks 2 R&D Deals, BioNTech To Buy Manufacturing Facility, Dyne Therapeutics IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 16)
Benzinga · 3d ago
The Daily Biotech Pulse: Moderna Expands Into Switzerland, Tiziana To Spin Off Testing Unit, Metacrine IPO
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 15) * Avidity Biosciences Inc (NASDAQ: RNA) * Beigene Ltd (NASDAQ: BGNE) * Bicycle Therapeutics PLC (NASDAQ: BCYC) * BioLife Solutions Inc (NASDAQ: BLFS) * Checkpoint Therapeutics Inc (NASDAQ: CKPT) * Denali Therapeutics Inc (NASDAQ:
Benzinga · 4d ago
Is Marinus Stock Still Worth Buying After Its 50% Rally? This Analyst Says Yes
The market pendulum is swinging from one side to the other, making it difficult to predict its trajectory from one session to the next. However, in the all or nothing world of biotechs, some things will always remain the same. Case in point: Marinus Pharmaceuticals (MRNS) shares surged nearly 50% in
TipRanks · 5d ago
MYO, FDX, NKLA and VERI among after-hours movers
Gainers: [[MYO]] +64.9%. [[AMCX]] +16.5%. [[INO]] +8.9%. [[FDX]] +8.8%. [[FWONA]] +8.7%.Losers: [[NKLA]] -6.1%. [[STSA]] -5.4%. [[SPWH]] -5.0%. [[VERI]] -4.5%. [[MRNS]] -3.8%.
Seekingalpha · 5d ago
Marinus Pharmaceuticals, Plus Therapeutics among healthcare gainers, Nano-X Imaging, Vaxart lead losers
Gainers: Marinus Pharmaceuticals (MRNS) +83%, Plus Therapeutics (PSTV) +24%, Inovio Pharmaceuticals (INO) +21%, Arbutus Biopharma ABUS +15%, Bellicum Pharmaceuticals (BLCM) +15%.Losers: Nano-X Imaging (NNOX) -24%, Vaxart (VXRT) -14%, Cassava Sciences (SAVA) -14%, 89bio, Inc. (ETNB) -12%, Replimune Group, Inc. (REPL) -8%.
Seekingalpha · 5d ago
Looking Into Marinus Pharmaceuticals's Return On Capital Employed
During Q2, Marinus Pharmaceuticals (NASDAQ: MRNS) brought in sales totaling $0.00. However, earnings decreased 15.76%, resulting in a loss of $15.88 million. In Q1, Marinus Pharmaceuticals brought in $0.00 in sales but lost $18.85 million in earnings.What Is Return On Capital Employed? Return on Capital
Benzinga · 5d ago
Marinus Pharmaceuticals (MRNS) Soars: Stock Adds 5.5% in Session
Marinus Pharmaceuticals (MRNS) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Zacks · 5d ago
The Daily Biotech Pulse: Marinus Epilepsy Study Meets Goal, Novavax Reaches Vaccine Manufacturing Deal, Outset Medical's IPO
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 14) * 10X Genomics Inc (NASDAQ: TXG) * Applied Molecular Transport Inc. (NASDAQ: AMTI) * Avenue Therapeutics Inc (NASDAQ: ATXI) * Avidity Biosciences Inc (NASDAQ: RNA) * BioLife Solutions Inc (NASDAQ: BLFS) * Denali Therapeutics Inc
Benzinga · 5d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Analyst Rating

Based on 9 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MRNS stock price target is 7.25 with a high estimate of 9.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 136
Institutional Holdings: 110.58M
% Owned: 90.50%
Shares Outstanding: 122.19M
TypeInstitutionsShares
Increased
37
18.00M
New
35
10.74M
Decreased
19
2.29M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.38%
Pharmaceuticals & Medical Research
+0.57%
Key Executives
Chairman/Director
Nicole Vitullo
President/Chief Executive Officer/Director
Scott Braunstein
Chief Financial Officer
Edward Smith
Vice President/General Counsel/Secretary
Martha Manning
Vice President/Director of Investor Relations
Sasha Damouni Ellis
Other
Joseph Hulihan
Director
Charles Austin
Independent Director
Enrique Carrazana
Independent Director
Michael Dougherty
Independent Director
Elan Ezickson
Independent Director
Seth Fischer
Independent Director
Timothy Mayleben
  • Dividends
  • Splits
  • Insider Activity
No Data

Analyst Price Target

The average MRNS stock price target is 7.25 with a high estimate of 9.00 and a low estimate of 5.00.

Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About MRNS
Marinus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings. Ganaxolone acts on the GABAA receptor, a target in the brain known for both anti seizure and anti anxiety effects through positive allosteric modulation. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19 pediatric epilepsy.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Marinus Pharmaceuticals Inc stock information, including NASDAQ:MRNS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MRNS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MRNS stock methods without spending real money on the virtual paper trading platform.